Company: BDRX
Filing Date: 2025-04-29
Form Type: POS AM
Source: 0001214659-25-006581
Chunk: 28

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-04-29
Form: POS AM
Chunk 28
---
 available for distribution equal to or greater than the amount of the proposed dividend.

| 19 |

<div align='center'>CAPITALIZATION</div>

The following table sets forth our capitalization
as of December 31, 2024. The information in this table should be read in conjunction with our “Management Discussion and Analysis
of Financial Condition and Results of Operations” and our consolidated financial statements and notes thereto and other financial
information incorporated by reference into this prospectus.

| (£ in thousands)          |     | As of December 31, 2024 |       |
|:--------------------------|:----|:------------------------|------:|
| Cash and cash equivalents |     |                         | 1,669 |
| Long-term debt            |     |                         |   118 |
| Total equity              |     |                         | 8,322 |
| Total capitalization      |     |                         | 8,440 |

The table above does not include, as of December
31, 2024:

| · | 328,823,388 Ordinary Shares issuable upon the exercise of stock options outstanding under our equity incentive plans at a weighted-average 
 exercise price of £0.005 per share;                                                                                                        |

| · | 99 Ordinary Shares issuable upon the exercise of stock options in connection with the acquisition of Dara (as defined below) at a 
 weighted average exercise price of $877.13 per share; and                                                                         |

| · | warrants, including pre-funded warrants, exercisable for 770,026 Depositary                                               
 Shares (representing 7,700,260,000 Ordinary Shares), at a weighted average exercise price of $38.42 per Depositary Share. |

| 20 |

<div align='center'>DESCRIPTION OF SHARE CAPITAL</div>

The following describes our issued share capital, summarizes the material provisions of our Articles of Association and highlights certain differences in corporate law in the United Kingdom and the United States. This description of our share capital and summary of our Articles of Association is not complete, and is qualified by reference to our Articles of Association. You should read our Articles of Association, which are filed as an exhibit to the registration statement of which this prospectus forms a part, for the provisions that are important to you.

The following describes our issued share capital, summarizes the material provisions of our articles of association and highlights certain differences in corporate law in the United Kingdom and the United States. Please note that this summary is not intended to be exhaustive. For further information please